Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms among patients with chronic heart failure with reduced ejection fraction, when compared to the gold-standard angiotensin-converting enzyme inhibitor, enalapril.
EditorsEditor-in-Chief Christopher O’Connor, MD, FACC
Executive Editor Mona Fiuzat, PharmD, FACC
JACC Heart Failure CME Editors
Tariq Ahmad, MD, MPH
Adam DeVore, MD
Abhinav Sharma, MD
Mitchell Psotka, MD, PhD
Kishan Parikh, MD
AuthorsKieran F. Docherty MBChB
Muthiah Vaduganathan, MD MPH
Important Dates
Date of Release: September 28, 2020
Term of Approval/Date of CME/MOC/ECME Expiration: September 27, 2021